Advertisement
Annovis Bio Says FDA Authorizes Phase 2/3 Trial For Buntanetap In Alzheimer's Disease
(RTTNews) - Annovis Bio, Inc. (ANVS), a late-stage clinical drug platform company, announced Thursday that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease (AD).
Following the submission of the Phase 2a clinical safety data and the chronic toxicology data in animals, the Company requested approval to further pursue the development of buntanetap in AD.
The FDA approved the Company's development plan, study protocol and authorized the initiation of the Phase 2/3 clinical study of buntanetap in AD.
For More Such Health News, visit rttnews.com
read more
Annovis Bio Says Phase III Study Data Release For Buntanetap In Parkinson's Disease Postponed
Drug platform company Annovis Bio, Inc. (ANVS) announced Wednesday a postponement in the Phase III study data release for buntanetap in Parkinson's Disease. This adjustment is due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results.
RTTNews
|
572 วันที่ผ่านมา
Australian Dollar Falls Against Majors
The Australian dollar weakened against other major currencies in the Asian session on Tuesday.
RTTNews
|
1 ชม. 12 นาทีที่ผ่านมา
European Shares Seen Higher At Open
European stocks may open flat to slightly higher on Tuesday after U.S. President Donald Trump described his recent meeting with Ukrainian President Volodymyr Zelenskyy and European partners as 'very good" and said he's begun arranging a meeting between Zelensky and Russian President Vladimir Putin, possibly within the next two weeks.
RTTNews
|
1 ชม. 44 นาทีที่ผ่านมา
Australia Consumer Sentiment At 3 1/2 Year High: Westpac
Australia's consumer confidence improved to a three-and-a-half year high in August as the central bank is expected to lower rates further after a third cut this year, monthly survey results from Westpac showed on Tuesday. The Westpac-Melbourne Institute Consumer Sentiment Index rose to 98.5 in August from 93.1 in June.
RTTNews
|
2 ชม. 15 นาทีที่ผ่านมา
Sensex, Nifty Slightly Higher In Early Trade
Indian shares were slightly higher on Tuesday, extending the previous session's strong gains after the Modi government, in a bold Independence Day declaration, revealed plans for the largest tax overhaul since 2017.
RTTNews
|
2 ชม. 40 นาทีที่ผ่านมา
Australian Market Trims Early Losses In Mid-market
The Australian stock market is trimming its early losses in mid-market trading on Tuesday, extending the losses in the previous session, following the mixed cues from Wall Street overnight. The benchmark S&P/ASX 200 is falling to near the 8,900 level, with weakness in mining and energy stocks partially offset by gains in financial stocks.
RTTNews
|
3 ชม. 48 นาทีที่ผ่านมา
Asian Markets Trade Mostly Higher
Asian stock markets are trading mostly higher on Tuesday, following the mixed cues from Wall Street overnight, amid optimism of a truce in the conflict between Russia and Ukraine with US President Donald Trump planning a summit meeting between Russian President Vladimir Putin and Ukrainian President Volodymyr Zelenskiy very soon. Asian markets closed mostly higher on Monday.
RTTNews
|
3 ชม. 59 นาทีที่ผ่านมา
Sensex, Nifty Likely To Open On Muted Note
Indian shares look set to open on a flat note on Tuesday, tracking muted cues from global markets.
RTTNews
|
4 ชม. 45 นาทีที่ผ่านมา
